In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
After finishing at $17.57 in the prior trading day, Summit Therapeutics Inc (NASDAQ: SMMT) closed at $17.38, down -1.08%. In other words, the price has decreased by -$1.08 from its previous closing price. On the day, 2.34 million shares were traded. SMMT stock price reached its highest trading level at $17.754 during the session, while it also had its lowest trading level at $17.24.
Ratios:
Our goal is to gain a better understanding of SMMT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.80 and its Current Ratio is at 3.80. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
On September 17, 2025, Barclays started tracking the stock assigning a Underweight rating and target price of $13.
On September 04, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $40.Guggenheim initiated its Buy rating on September 04, 2025, with a $40 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 21 ’25 when Xia Yu bought 533,617 shares for $18.74 per share. The transaction valued at 9,999,983 led to the insider holds 32,057,147 shares of the business.
DUGGAN ROBERT W bought 26,680 shares of SMMT for $499,983 on Oct 21 ’25. The Co-Chief Executive Officer now owns 76,680 shares after completing the transaction at $18.74 per share. On Oct 21 ’25, another insider, Zanganeh Mahkam, who serves as the Co-Chief Executive Officer of the company, bought 26,680 shares for $18.74 each. As a result, the insider paid 499,983 and bolstered with 76,680 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SMMT now has a Market Capitalization of 12938411008 and an Enterprise Value of 12705285120.
Stock Price History:
The Beta on a monthly basis for SMMT is -1.51, which has changed by -0.053850293 over the last 52 weeks, in comparison to a change of 0.12838376 over the same period for the S&P500. Over the past 52 weeks, SMMT has reached a high of $36.91, while it has fallen to a 52-week low of $15.55. The 50-Day Moving Average of the stock is -8.20%, while the 200-Day Moving Average is calculated to be -20.76%.
Shares Statistics:
The stock has traded on average 3.32M shares per day over the past 3-months and 2752670 shares per day over the last 10 days, according to various share statistics. A total of 744.44M shares are outstanding, with a floating share count of 102.73M. Insiders hold about 86.17% of the company’s shares, while institutions hold 14.08% stake in the company. Shares short for SMMT as of 1764288000 were 32347593 with a Short Ratio of 9.74, compared to 1761868800 on 32436319. Therefore, it implies a Short% of Shares Outstanding of 32347593 and a Short% of Float of 27.310000000000002.
Earnings Estimates
A detailed examination of Summit Therapeutics Inc (SMMT) is currently in progress, with 11.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.04, with high estimates of $0.71 and low estimates of -$0.27.
Analysts are recommending an EPS of between -$0.1 and -$1.12 for the fiscal current year, implying an average EPS of -$0.77. EPS for the following year is -$0.74, with 10.0 analysts recommending between -$0.43 and -$1.18.
Revenue Estimates
Based on 12 analysts’ estimates, the company’s revenue will be $1.89M in the next fiscal year. The high estimate is $44.12M and the low estimate is -$62.12M.
